Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
Research output: Contribution to journal › Journal article › Research › peer-review
In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.
| Original language | English |
|---|---|
| Journal | Multiple Sclerosis |
| Volume | 17 |
| Issue number | 9 |
| Pages (from-to) | 1074-8 |
| Number of pages | 5 |
| ISSN | 1352-4585 |
| DOIs | |
| Publication status | Published - 2011 |
ID: 40194283